{{item.title}}
Acino, a Swiss pharmaceutical company, entered into an agreement to acquire M8 Pharmaceuticals, a portfolio company of Montreux Growth Partners. The PwC Deals team, led by Luca Borrelli, supported Acino with Financial Due Diligence, SPA advise, Tax Due Diligence and Structuring, Pension Due Diligence, as well as Deal Analytics.
M8 Pharmaceuticals is a fast-growing specialty biopharmaceutical company, headquartered in Mexico City and focused on licensing, marketing, and distributing innovative and established medicines in Mexico and Brazil. M8 Pharmaceuticals has a highly successful record of signing exclusive licensing agreements with large pharmaceutical and biotech companies for the rights to market and commercialize products in Mexico and Brazil. The company brings a portfolio of well-known proven brands and innovative medicines, a best-in-class deal-making platform, and an outstanding reputation among its partners. Moreover, it has built a large pipeline across a broad range of key therapeutic areas, including CNS, cardiometabolism, respiratory, gastroenterology, oncology and hematology, and rare diseases.
Through this acquisition, Acino will enter the two largest pharmaceutical markets in Latin America, significantly expanding its geographic footprint and strengthening its position in the region. The acquisition will complement Acino’s existing Latin American division, which operates across eight countries.
Financial due diligence / SPA advice
Tax due dilligence and structuring
Deal Analytics
Financial and Tax international
Luca Borrelli
Partner, Deals Pharma and Life Sciences Leader, PwC Switzerland
Tel: +41 58 792 22 78